Nabriva Therapeutics is a biopharma company developing a new class of antibiotics (pleuromutilins) for the treatment of patients with serious infections caused by multi-drug resistant pathogens.

Nabriva Therapeutics – pleuromutilins against multi-drug resistant pathogens

Pleuromutilins represent a new class of antibiotics, inhibiting bacterial protein synthesis by binding to unique sites on the 50S subunit of the ribosome. These new antibiotics display a very low potential for resistance development and they have a very low potential for cross-resistance with other established antibacterial classes. Nabriva Therapeutics is the first company with proof of concept achieved for the systemic use of pleuromutilins in patients. Two pleuromutilins from Nabriva, BC‑7013 and lefamulin, have shown excellent results in clinical studies. Lefamulin (BC‑3781) is ideally positioned for the systemic treatment of acute bacterial skin and skin structure infections (ABSSSI) as well as community-acquired bacterial pneumonia (CABP) or hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). Lefamulin is about to enter Phase 3 clinical trial. BC‑7013 was developed as a topical treatment of dermatological diseases and has already completed Phase 1 trials. Since Nabriva´s pleuromutilin antibiotics are available as both oral and intra-venous formulations and have an ideal anti-bacterial spectrum for both skin and respiratory infections, they address a significant medical need and constitute an excellent commercial opportunity.

Nabriva Therapeutics is a privately held biotech company founded in 2006 as a spin-out of Sandoz GmbH. Nabriva is backed by international investors (HBM Partners, Phase4 Partners, Novartis Venture Fund, Wellcome Trust, Global Life Science Ventures and Sandoz). Nabriva is headquartered in Vienna (Austria). Management Team is composed by Colin Broom, Ralf Schmid, William Prince, Steven Gelone, Werner Heilmayer and Stefan Reisinger. Supervisory Board is composed by Denise Pollard-Knight, Axel Bolte, Chen Yu, Chau Quang Khuong, David Chiswell, George Talbot and Charles Rowland. Nabriva just announced the successful completion of a $120 million Series B financing led by Vivo Capital and OrbiMed. The initial tranche of $50 million will enable Nabriva to progress its lead product, lefamulin, into clinical phase 3 studies in community-acquired bacterial pneumonia (CABP), but also to continue the development of its product pipeline.

More about Nabriva Therapeutics: www.nabriva.com

Nabriva Therapeutics – pleuromutilins – multi-drug resistant pathogens – BC‑7013 – lefamulin – BC‑3781

Nabriva Therapeutics – Nabriva – pleuromutilins – pleuromutilin – antibiotics – antibiotic – multi-drug resistant pathogen – multi drug resistant pathogens – 50S subunit ribosome – 50S ribosome – BC‑7013 – lefamulin – BC7013 – BC‑3781 – BC3781 – acute bacterial skin and skin structure infections – ABSSSI – acute bacterial skin and skin structure infection – acquired bacterial pneumonia – CABP – hospital-acquired bacterial pneumonia – ventilator-associated bacterial pneumonia – HABP – VABP – pleuromutilin antibiotics – pleuromutilin antibiotic – Sandoz GmbH – Sandoz – HBM Partners – Phase4 Partners – Novartis Venture Fund – Wellcome Trust – Global Life Science Ventures – Colin Broom – Ralf Schmid – William Prince – Steven Gelone – Werner Heilmayer – Stefan Reisinger – Denise Pollard-Knight – Axel Bolte – Chen Yu – Chau Quang Khuong – David Chiswell – George Talbot – Charles Rowland – Vivo Capital – OrbiMed